Literature DB >> 19439478

The M33 chemokine receptor homolog of murine cytomegalovirus exhibits a differential tissue-specific role during in vivo replication and latency.

Rhonda D Cardin1, Gregory C Schaefer, Janelle R Allen, Nicholas J Davis-Poynter, Helen E Farrell.   

Abstract

M33, encoded by murine cytomegalovirus (MCMV), is a member of the UL33 homolog G-protein-coupled receptor (GPCR) family and is conserved across all the betaherpesviruses. Infection of mice with recombinant viruses lacking M33 or containing specific signaling domain mutations in M33 results in significantly diminished MCMV infection of the salivary glands. To determine the role of M33 in viral dissemination and/or infection in other tissues, viral infection with wild-type K181 virus and an M33 mutant virus, DeltaM33B(T2), was characterized using two different routes of inoculation. Following both intraperitoneal (i.p.) and intranasal (i.n.) inoculation, M33 was attenuated for infection of the spleen and pancreas as early as 7 days after infection. Following i.p. inoculation, DeltaM33B(T2) exhibited a severe defect in latency as measured by a diminished capacity to reactivate from spleens and lungs in reactivation assays (P < 0.001). Subsequent PCR analysis revealed markedly reduced DeltaM33B(T2) viral DNA levels in the latently infected spleens, lungs, and bone marrow. Following i.n. inoculation, latent DeltaM33B(T2) viral DNA was significantly reduced in the spleen and, in agreement with results from i.p. inoculation, did not reactivate from the spleen (P < 0.001). Furthermore, in vivo complementation of DeltaM33B(T2) virus replication and/or dissemination to the salivary glands and pancreas was achieved by coinfection with wild-type virus. Overall, our data suggest a critical tissue-specific role for M33 during infection in the salivary glands, spleen, and pancreas but not the lungs. Our data suggest that M33 contributes to the efficient establishment or maintenance of long-term latent MCMV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439478      PMCID: PMC2708650          DOI: 10.1128/JVI.00386-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

1.  Cytomegalovirus encodes a potent alpha chemokine.

Authors:  M E Penfold; D J Dairaghi; G M Duke; N Saederup; E S Mocarski; G W Kemble; T J Schall
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Depletion of extracellular RANTES during human cytomegalovirus infection of endothelial cells.

Authors:  M A Billstrom; L A Lehman; G Scott Worthen
Journal:  Am J Respir Cell Mol Biol       Date:  1999-08       Impact factor: 6.914

3.  The murine cytomegalovirus chemokine homolog, m131/129, is a determinant of viral pathogenicity.

Authors:  P Fleming; N Davis-Poynter; M Degli-Esposti; E Densley; J Papadimitriou; G Shellam; H Farrell
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Human cytomegalovirus encodes a highly specific RANTES decoy receptor.

Authors:  Dai Wang; Wade Bresnahan; Thomas Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-09       Impact factor: 11.205

5.  Cytomegalovirus-encoded beta chemokine promotes monocyte-associated viremia in the host.

Authors:  N Saederup; Y C Lin; D J Dairaghi; T J Schall; E S Mocarski
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

6.  Human herpesvirus 7 open reading frames U12 and U51 encode functional beta-chemokine receptors.

Authors:  Kenjiro Tadagaki; Kazushi Nakano; Koichi Yamanishi
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

7.  Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception.

Authors:  Alec J Redwood; Martin Messerle; Nicole L Harvey; Christopher M Hardy; Ulrich H Koszinowski; Malcolm A Lawson; Geoffrey R Shellam
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

8.  Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33.

Authors:  Daniel N Streblow; Craig N Kreklywich; Patricia Smith; Jordana L Soule; Christine Meyer; Michael Yin; Patrick Beisser; Cornelis Vink; Jay A Nelson; Susan L Orloff
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

9.  Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene.

Authors:  J Vieira; T J Schall; L Corey; A P Geballe
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

10.  Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells.

Authors:  B Bodaghi; T R Jones; D Zipeto; C Vita; L Sun; L Laurent; F Arenzana-Seisdedos; J L Virelizier; S Michelson
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  35 in total

1.  Development of a Primary Human Cell Model for the Study of Human Cytomegalovirus Replication and Spread within Salivary Epithelium.

Authors:  Kristen M Morrison; Matthew J Beucler; Emily O Campbell; Margaret A White; Rachel E Boody; Keith C Wilson; William E Miller
Journal:  J Virol       Date:  2019-01-17       Impact factor: 5.103

2.  Partial functional complementation between human and mouse cytomegalovirus chemokine receptor homologues.

Authors:  Helen E Farrell; Alexander M Abraham; Rhonda D Cardin; Alexander H Sparre-Ulrich; Mette M Rosenkilde; Katja Spiess; Tine H Jensen; Thomas N Kledal; Nicholas Davis-Poynter
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

3.  Methods for Studying the Function of Cytomegalovirus GPCRs.

Authors:  Christine M O'Connor; William E Miller
Journal:  Methods Mol Biol       Date:  2021

4.  Identification of common mechanisms by which human and mouse cytomegalovirus seven-transmembrane receptor homologues contribute to in vivo phenotypes in a mouse model.

Authors:  Helen E Farrell; Alexander M Abraham; Rhonda D Cardin; Ann-Sofie Mølleskov-Jensen; Mette M Rosenkilde; Nicholas Davis-Poynter
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

Review 5.  Herpesvirus-encoded GPCRs: neglected players in inflammatory and proliferative diseases?

Authors:  Henry F Vischer; Marco Siderius; Rob Leurs; Martine J Smit
Journal:  Nat Rev Drug Discov       Date:  2014-01-21       Impact factor: 84.694

6.  The human cytomegalovirus US27 gene product enhances cell proliferation and alters cellular gene expression.

Authors:  Angela P Lares; Carolyn C Tu; Juliet V Spencer
Journal:  Virus Res       Date:  2013-07-11       Impact factor: 3.303

7.  The human cytomegalovirus-encoded G protein-coupled receptor UL33 exhibits oncomodulatory properties.

Authors:  Jeffrey R van Senten; Maarten P Bebelman; Tian Shu Fan; Raimond Heukers; Nick D Bergkamp; Puck van Gasselt; Ellen V Langemeijer; Erik Slinger; Tonny Lagerweij; Afsar Rahbar; Marijke Stigter-van Walsum; David Maussang; Rob Leurs; René J P Musters; Guus A M S van Dongen; Cecilia Söderberg-Nauclér; Thomas Würdinger; Marco Siderius; Martine J Smit
Journal:  J Biol Chem       Date:  2019-09-13       Impact factor: 5.157

Review 8.  Autoimmunity and infection in Sjögren's syndrome.

Authors:  Ann Igoe; R Hal Scofield
Journal:  Curr Opin Rheumatol       Date:  2013-07       Impact factor: 5.006

9.  Activation of intracellular signaling pathways by the murine cytomegalovirus G protein-coupled receptor M33 occurs via PLC-{beta}/PKC-dependent and -independent mechanisms.

Authors:  Joseph D Sherrill; Melissa P Stropes; Olivia D Schneider; Diana E Koch; Fabiola M Bittencourt; Jeanette L C Miller; William E Miller
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection.

Authors:  Rhonda D Cardin; Fernando J Bravo; Andrea P Sewell; James Cummins; Louis Flamand; Jean-Marc Juteau; David I Bernstein; Andrew Vaillant
Journal:  Virol J       Date:  2009-12-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.